MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-12-31, VIVS had -$2,389K decrease in cash & cash equivalents over the period. -$2,271K in free cash flow.

Cash Flow Overview

Change in Cash
-$2,389K
Free Cash flow
-$2,271K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-12-31
2025-09-30
2025-06-30
Net loss
-2,691 -2,545 -2,843
Interest accretion on escrow receivable
3 4 4
Accretion on investments
0 0 0
Write-downs of inventory
0 0 -
Depreciation and amortization
52 59 61
Stock-based compensation
67 72 78
Non-cash lease expense
116 114 112
Accounts receivable
1 0 2
Inventory
0 0 0
Prepaid expenses and other assets
-174 -97 -248
Accounts payable
91 -93 -971
Accrued expenses
47 44 -499
Operating lease liabiliy
-123 -122 -120
Net cash used in operating activities
-2,271 -2,378 -3,940
Purchases of fixed assets
0 0 -
Purchases of investments
0 0 0
Maturities of investments
0 0 0
Net cash provided by investing activities
0 0 0
Proceeds from issuance of common stock, net
0 0 1,811
Repayment of insurance premium financing liability
118 0 128
Net cash provided by financing activities
-118 0 1,683
Net decrease in cash, cash equivalents, and restricted cash
-2,389 -2,378 -2,257
Cash and cash equivalents at beginning of period
6,820 11,455 -
Cash and cash equivalents at end of period
4,431 6,820 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

VivoSim Labs, INC. (VIVS)

VivoSim Labs, INC. (VIVS)